Our Journey
Explore the milestones that have shaped Jodas into a globally trusted pharmaceutical company.
2006
INDIA
Jodas Expoim began its journey as a speciality generic Pharmaceutical in October 2006. Russia was our first commercial market and we commenced our operation with Cephalosporin Antibiotics,initially manufacturing approximately 5-10 Million units. Guided by our philosophy of “One step better” we have remained committed to deliver innovative, high-quality and effective generic formulations for the past two decades.
2007
RUSSIA
We expanded our establishments by opening a subsidiary and regional office in Russia. This milestone contributed exponentially to the company’s growth, enhancing regional operations and accelerating international growth.
2012
INDIA
We laid the foundation for our Greenfield Global Manufacturing facility in Hyderabad. Establishing our own manufacturing facility strengthened quality control and marked a major transition from third party manufacturing. Hyderabad, being the ‘Vaccine Hub of India’ also made it a geographically ideal location for this milestone.
2014
RUSSIA
We expanded our presence to over 50 cities across Russia while actively focusing on hospital supplies. During this phase, we also secured 68 product registrations in Russia, which significantly broadened our portfolio and market reach. These milestones strengthened our presence in Russia and established Jodas as a top pharmaceutical partner.
2015 - 2018
INDIA
We completed multiple phases of expansion across all our manufacturing units, significantly enhancing our production capabilities and operational excellence. In 2017, we achieved the prestigious EU GMP certification, reaffirming our commitment to global quality standards. As EU GMP is recognized by regulatory authorities in numerous countries, the certification unlocked direct access to new global markets and created opportunities for broader international expansion. It marked a significant step in positioning Jodas Expoim as a globally trusted pharmaceutical manufacturer.
2019 - 2020
EXPANDING THROUGH THE PANDEMIC
We secured the SFDA (Saudi Food and Drug Authority) approval in 2019, which was a significant milestone in our journey into the Middle East. Building on our EU GMP-compliant manufacturing standards, we completed our UAE registration, enabling commercial operations across the MENA (Middle East and North Africa) region. In 2020, during the COVID-19 pandemic, we developed our transportation and packaging processes and complied with global laws and regulations to ensure uninterrupted product availability and supply in the market. Despite the unprecedented global challenges, Jodas was committed to delivering high-quality medicines to patients across international markets.
2021
RUSSIA
We received the reissuance of Russian GMP certification for all manufacturing blocks. This ensured uninterrupted business operations and continued access to the Russian market. The certification reinforced our commitment to maintaining the highest quality standards and strengthened our long-standing presence in the region.
2022
GLOBAL
Our demand in the global market had multiplied leading to a significant global milestone i.e Global Recognition. We had 250+ approved molecules and an expanding presence across 25+ countries. During this phase, our strongest markets included Russia, the EAEU region, LATAM, MENA, Saudi Arabia, and Africa. We also expanded our manufacturing capabilities into Russia and the CIS region, improving efficiency and placing ourselves as one of Russia's top pharmaceutical companies. This period improved our regulatory footprint, gave us access to key international markets, and marked a new phase of global recognition and growth for Jodas Expoim.
2023 - 2025
INDIA
We strengthened our global presence by securing ANVISA (Brazil) approvals for our Oncology, General Injectable and Cephalosporin manufacturing blocks. We also expanded our international compliance with TMDA (Tanzania) approvals and the reissuance of GMP certifications from EAEU and European authorities across all our manufacturing blocks. During this period, we launched our contract media and Oncology products in the domestic market to address the growing demand for these specialised therapies. Looking ahead, we remain committed to introducing new products every year, as we continue to expand into more international markets.
Regulatory Approvals
